Follistatin 344 Dosage Guide
Evidence-based protocols for the myostatin inhibitor — realistic expectations, cycling strategies, stacking with IGF-1 LR3 and MK-677, reproductive considerations, and what the research actually shows.
In This Guide
What Is Follistatin?
Follistatin 344 (FST-344) is a recombinant form of Follistatin, a naturally occurring glycoprotein that binds and neutralizes members of the TGF-β superfamily — most notably myostatin and activin. By inhibiting myostatin (a powerful negative regulator of muscle growth), Follistatin theoretically removes the “brake” on skeletal muscle hypertrophy, allowing enhanced muscle growth potential.
The science behind myostatin inhibition is compelling. Myostatin knockout animals (notably the “mighty mouse” and Belgian Blue cattle) display dramatically increased muscle mass. Follistatin gene therapy trials in muscular dystrophy patients have shown meaningful improvements in muscle function. However, there is a critical distinction that must be made: the translation from myostatin biology and gene therapy results to exogenous Follistatin peptide injection in humans is far less established. Most human evidence comes from gene therapy, not subcutaneous peptide injection.
Follistatin also plays important roles beyond muscle. It modulates FSH (follicle-stimulating hormone) through activin neutralization, influences inflammation and fibrosis pathways, and participates in tissue remodeling. These broader effects — particularly the reproductive implications — are important safety considerations for anyone using exogenous Follistatin.
Use our Peptide Dosage to calculate your exact dose based on vial size and concentration.
Key Characteristics:
- Myostatin inhibitor — binds and neutralizes myostatin, removing the primary negative regulator of skeletal muscle growth
- Activin binder — also neutralizes activin, affecting FSH regulation, inflammation, and fibrosis pathways
- Large glycoprotein — FS-344 is approximately 344 amino acids (before processing) — significantly larger and more complex than typical synthetic peptides
- Recombinant production — manufactured through recombinant expression systems, making it one of the most expensive research peptides per milligram
- Short half-life — relatively rapid clearance requiring daily dosing during cycles; FS-344 is cleaved in vivo to FS-315 (serum form) and FS-288 (tissue-bound form)
- Limited human injection data — strong myostatin biology, promising gene therapy results, but minimal controlled human data for subcutaneous peptide injection protocols
For a complete overview of its mechanism and research, see our full Follistatin 344 profile. New to peptides? Start with the Beginner's Guide to Peptides.
How Follistatin Dosage Is Determined
Unlike peptides with robust human dose-response data (such as Hexarelin or Ipamorelin), Follistatin 344 dosing for subcutaneous injection is not derived from controlled human clinical trials. The commonly cited dosage ranges come from a combination of animal research, gene therapy dose extrapolation, pharmacokinetic estimates, and community experience.
Animal & Preclinical Research
The foundational myostatin research comes from animal models. Lee & McPherron demonstrated that Follistatin overexpression in mice produced significant muscle mass increases — even exceeding the effects of myostatin knockout alone, suggesting Follistatin inhibits additional TGF-β family members beyond myostatin. These studies established the biological rationale but used transgenic overexpression or viral vector delivery, not exogenous peptide injection.
Gene Therapy Trials
Mendell et al. conducted AAV-delivered Follistatin gene therapy trials in patients with Becker muscular dystrophy and inclusion body myositis. These trials demonstrated measurable improvements in muscle function and the 6-minute walk test. However, gene therapy produces sustained, high local expression of Follistatin in muscle tissue over extended periods — a fundamentally different pharmacokinetic profile from a transient subcutaneous injection.
Community-Derived Dosing
The 100–200 mcg daily dosage range used in community protocols is based on pharmacokinetic estimates, affordability constraints (Follistatin is expensive), and user-reported experiences. There are no published human dose-response studies for subcutaneous Follistatin 344 injection. The dosing is essentially empirical — community consensus rather than clinical evidence.
Standard Follistatin 344 Dosage Ranges
Follistatin 344 is administered by subcutaneous injection, typically once daily during short cycles. The most commonly reported dosage range is 100–200 mcg per day. Some protocols use twice-daily dosing at 100 mcg each. Higher doses up to 300 mcg daily have been reported but carry more unknowns with no established benefit ceiling.
Dosage by Experience Level
| Level | Dose per Day | Frequency | Cycle Length | Notes |
|---|---|---|---|---|
| Conservative | 100 mcg | 1x daily (SubQ) | 10–14 days | Assess tolerance; lowest risk starting point |
| Standard | 100–200 mcg | 1x daily (SubQ) | 10–20 days | Most common community protocol; balances cost and exposure |
| Aggressive | 200–300 mcg | 1–2x daily (SubQ) | 20–30 days | Higher exposure; more unknowns; significantly higher cost |
Administration Notes
- Route: Subcutaneous injection (abdomen, thigh, or upper arm)
- Timing: Most protocols use morning administration; timing relative to meals is less critical than with GHRPs
- Consistency: Daily dosing during the cycle is more important than specific time-of-day timing
- Reconstitution: Add bacteriostatic water gently down the side of the vial — do not spray directly onto the powder or shake. Swirl gently.
- Storage: Refrigerate after reconstitution (2–8°C). Do not freeze reconstituted solution. Use within 14–21 days.
Verified sources for Follistatin
These vendors are vetted by PeptideWiki for purity testing and COA transparency.
Follistatin Variants Explained
Follistatin exists in multiple isoforms, each with different tissue distribution, binding properties, and biological activity. Understanding the variants is important because the form you inject (FS-344) is not the same as the form that circulates systemically or acts in reproductive tissue.
| Variant | Amino Acids | Distribution | Key Properties |
|---|---|---|---|
| FS-344 | 344 (precursor) | Injected form; cleaved in vivo | Most common research/community variant; processed to FS-315 and FS-288 after injection |
| FS-315 | 315 | Primary circulating serum form | Main systemic myostatin-binding form; does not bind heparan sulfate proteoglycans, so it circulates freely |
| FS-288 | 288 | Tissue-bound; concentrated in gonads | Binds heparan sulfate proteoglycans on cell surfaces; predominantly involved in gonadal activin regulation and FSH modulation |
Why FS-344 Is the Standard Variant
FS-344 is the precursor form that the body naturally processes into the functional variants. When injected subcutaneously, FS-344 is cleaved to produce both FS-315 (which enters circulation and can bind myostatin systemically) and FS-288 (which localizes to tissues, particularly the gonads). Using FS-344 as the injectable form allows the body to generate both functional variants through its natural processing pathways.
The Reproductive Connection (FS-288 & Activin)
The FS-288 variant produced from FS-344 processing concentrates in reproductive tissue, where it binds activin. This activin binding modulates FSH secretion, which is critical for both female follicular development and male spermatogenesis. This is why Follistatin use carries theoretical reproductive considerations — the FS-288 produced from injected FS-344 directly affects the gonadal activin-follistatin axis.
Calculate Your Follistatin 344 Dose
Follistatin 344 is supplied as a lyophilized (freeze-dried) powder, typically in 1 mg vials (due to cost, larger vials are less common than with other peptides). You reconstitute it with bacteriostatic water, then draw your dose using an insulin syringe. Handle the reconstitution gently — Follistatin is a large protein that can be denatured by vigorous agitation.
Worked Example:
- Vial size: 1 mg (1,000 mcg) of Follistatin 344
- Bacteriostatic water added: 1 mL
- Concentration: 1,000 mcg ÷ 1 mL = 1,000 mcg per mL
- Target dose: 100 mcg
- Volume to draw: 100 ÷ 1,000 = 0.1 mL = 10 units on an insulin syringe
Quick Reference — 1 mg Vial
| Bac Water Added | Concentration | 100 mcg Dose | 200 mcg Dose |
|---|---|---|---|
| 0.5 mL | 2,000 mcg/mL | 5 units (0.05 mL) | 10 units (0.1 mL) |
| 1 mL | 1,000 mcg/mL | 10 units (0.1 mL) | 20 units (0.2 mL) |
| 2 mL | 500 mcg/mL | 20 units (0.2 mL) | 40 units (0.4 mL) |
Skip the Math — Use Our
Enter your vial size, water volume, and desired dose — get instant calculations with zero manual math.
Follistatin 344 Dosage by Goal
Follistatin's primary appeal is myostatin inhibition for muscle growth, but its broader TGF-β modulation makes it relevant to other goals as well. The following protocols reflect community experience and theoretical rationale — remember that human injection data is limited for all of these applications.
Muscle Growth & Myostatin Inhibition
The primary use case for Follistatin 344. The goal is to achieve sufficient circulating Follistatin to meaningfully neutralize myostatin and allow enhanced muscle hypertrophy. This requires consistent daily dosing, adequate training stimulus, and proper nutrition. Myostatin inhibition removes a brake — it does not actively build muscle without the training signal.
- Dose: 100–200 mcg SubQ daily
- Cycle: 10–30 days (most common: 10–20 days)
- Cycles per year: 1–3 cycles with extended off-periods
- Requirements: Progressive overload training, caloric surplus, adequate protein intake (1.6–2.2 g/kg/day)
- Realistic expectations: Do not expect gene therapy or myostatin knockout results. Any effects from peptide injection will be subtle and develop over multiple cycles.
Body Recomposition & Fat Loss Support
Myostatin inhibition may support improved body composition by favoring lean mass retention and potentially enhancing fat oxidation. Follistatin's effects on activin may also influence metabolic pathways. This is a secondary application with even less human evidence than the muscle growth use case.
- Dose: 100 mcg SubQ daily
- Cycle: 10–20 days
- Context: Best used alongside a well-structured training program and moderate caloric deficit
- Note: Consider stacking with MK-677 for additional GH-mediated fat loss support (see stacking section)
Recovery & Anti-Fibrosis
Follistatin's TGF-β modulation extends beyond myostatin. By binding activin and other TGF-β ligands involved in fibrosis, Follistatin may support tissue remodeling and recovery. This is a research-stage application with animal model support but minimal human data.
- Dose: 100 mcg SubQ daily
- Cycle: 10–14 days
- Context: May complement a BPC-157 recovery protocol for injury rehabilitation
- Evidence level: Preclinical only. Animal models show anti-fibrotic effects. No human injection data for this application.
Muscle Wasting & Sarcopenia (Research Context)
The most medically relevant application of Follistatin is in conditions of pathological muscle wasting — muscular dystrophy, sarcopenia, cachexia, and age-related muscle loss. This is where gene therapy trials have shown the most promise. Peptide injection for this purpose remains speculative but has the strongest theoretical rationale.
- Dose: 100–200 mcg SubQ daily
- Cycle: 20–30 days (longer cycles for therapeutic contexts)
- Context: Always under medical supervision for pathological conditions. Not a replacement for standard medical treatment.
- Note: Gene therapy delivery (AAV-FS344) has shown meaningful results in clinical trials for Becker muscular dystrophy. Peptide injection results for muscle wasting are unvalidated.
Cycling Protocols
Follistatin 344 is universally used in short cycles with extended off-periods. This cycling approach reflects multiple considerations: the high cost of the peptide, theoretical concerns about prolonged myostatin suppression, potential reproductive effects from sustained activin binding, and the overall lack of long-term safety data for exogenous injection.
Cycling Protocols
| Protocol | On-Cycle | Off-Cycle | Cycles/Year | Notes |
|---|---|---|---|---|
| Short Burst | 10 days | 20–30 days off | 2–3 | Most conservative; minimal exposure; good first protocol |
| Standard | 20 days | 40–60 days off | 2–3 | Most common community protocol; balances exposure and cost |
| Extended | 30 days | 60–90 days off | 1–2 | Maximum cycle length; higher cost; more reproductive concerns |
Why the Off-Periods Are Long
The extended off-periods between Follistatin cycles serve several purposes:
- Reproductive axis recovery: Allow the activin-follistatin-inhibin axis to normalize, particularly FSH regulation
- Cost management: Follistatin 344 is one of the most expensive research peptides; short cycles with long breaks are more sustainable
- Safety margin: Given the limited human data, longer off-periods provide a margin of safety against unknown long-term effects
- Assessment window: The off-period allows you to evaluate what effects, if any, the cycle produced before committing to another
Timing Cycles for Maximum Effect
Many users time their Follistatin cycles to coincide with phases of intensified training or the beginning of a hypertrophy block. The rationale is that reducing myostatin during a period of high training stimulus may maximize the anabolic potential. Others time cycles during a caloric surplus phase to capitalize on the growth-permissive environment.
Follistatin 344 Stacking Protocols
Follistatin stacking aims to complement myostatin inhibition with other growth-promoting or recovery-supporting mechanisms. The theoretical rationale is that removing the myostatin brake (Follistatin) while simultaneously enhancing growth signals (IGF-1, GH) may produce synergistic effects. However, stacking multiple experimental compounds makes it impossible to attribute effects to any single agent.
Follistatin 344 + IGF-1 LR3 — Growth Factor Synergy
The most theoretically synergistic Follistatin stack. Follistatin 344 inhibits myostatin (removing the growth brake), while IGF-1 LR3 provides a direct anabolic growth signal through the IGF-1 receptor. The combined approach addresses both sides of the growth equation: removing inhibition and enhancing stimulation.
| Compound | Dose | Frequency | Purpose |
|---|---|---|---|
| Follistatin 344 | 100–200 mcg SubQ | 1x daily | Myostatin inhibition (remove growth brake) |
| IGF-1 LR3 | 20–50 mcg SubQ | 1x daily (post-workout or morning) | Direct anabolic growth signal via IGF-1 receptor |
Follistatin 344 + MK-677 — Myostatin Inhibition + GH Elevation
Combines Follistatin's myostatin inhibition with MK-677 (Ibutamoren)'s sustained GH and IGF-1 elevation. MK-677 is an oral GH secretagogue that raises baseline GH and IGF-1 levels, complementing Follistatin's myostatin-blocking mechanism. This is a more accessible stack since MK-677 is oral.
| Compound | Dose | Frequency | Purpose |
|---|---|---|---|
| Follistatin 344 | 100–200 mcg SubQ | 1x daily (during 10–20 day cycle) | Myostatin inhibition |
| MK-677 | 12.5–25 mg oral | 1x daily (continuous; before bed) | Sustained GH and IGF-1 elevation; improved sleep |
Follistatin 344 + BPC-157 (Growth Modulation + Tissue Repair)
Combines Follistatin's TGF-β modulation and anti-fibrotic potential with BPC-157's well-documented tissue repair and angiogenesis effects. This stack is oriented toward recovery and rehabilitation rather than pure muscle growth, leveraging Follistatin's broader biological activities beyond myostatin inhibition.
| Compound | Dose | Frequency | Purpose |
|---|---|---|---|
| Follistatin 344 | 100 mcg SubQ | 1x daily (during 10–14 day cycle) | TGF-β modulation, anti-fibrotic support |
| BPC-157 | 250 mcg SubQ | 1–2x daily (near injury site) | Localized tissue repair, angiogenesis, growth factor upregulation |
Follistatin 344 + GH Secretagogue Stack (Comprehensive Growth Support)
For users seeking maximum growth support, Follistatin can be combined with a GHRP + GHRH stack to simultaneously inhibit myostatin and elevate GH/IGF-1 through pituitary stimulation. This is the most comprehensive approach but also the most complex and expensive.
| Compound | Dose | Frequency | Purpose |
|---|---|---|---|
| Follistatin 344 | 100–200 mcg SubQ | 1x daily (during 10–20 day cycle) | Myostatin inhibition |
| Ipamorelin | 200–300 mcg SubQ | 2–3x daily (fasted) | Clean GH pulse (minimal side effects) |
| CJC-1295 (no-DAC) | 100 mcg SubQ | At each Ipamorelin injection | Amplifies and sustains GH pulse (GHRH mechanism) |
Explore more combinations with our Peptide Stack Builder or browse the Top 10 Peptide Stacks guide.
Safety, Side Effects & Contraindications
Reported & Theoretical Side Effects
Community-reported (generally well-tolerated at standard doses):
- Injection site reactions — redness, soreness, or minor swelling (common with SubQ injection of any peptide)
- Mild fatigue or lethargy — reported by some users, usually transient
- Temporary joint discomfort — reported infrequently; mechanism unclear
- Mild headache — usually resolves within the first few days
Theoretical concerns (based on mechanism of action):
- FSH suppression: Follistatin binds activin, which is critical for FSH regulation. Prolonged activin neutralization could suppress FSH, affecting fertility in both men (spermatogenesis) and women (follicular development, ovulation)
- Reproductive axis disruption: The FS-288 variant produced from FS-344 concentrates in gonadal tissue. Short cycles mitigate but may not eliminate this concern
- Potential for unchecked cell proliferation: TGF-β family members regulate cell growth. Chronic suppression of activin and myostatin could theoretically promote unwanted cell proliferation. This is a long-term concern, not an acute risk
- Effects on wound healing and fibrosis: TGF-β signaling is important for wound healing. Excessive TGF-β suppression could theoretically impair healing, though Follistatin's anti-fibrotic effects may be beneficial in some contexts
Contraindications
- Active cancer or history of cancer — Follistatin modulates TGF-β signaling pathways involved in cell growth regulation. Use in the presence of active malignancies is contraindicated.
- Pregnancy and breastfeeding — Follistatin's effects on activin and the reproductive axis make it strictly contraindicated during pregnancy and nursing. No safety data exists.
- Active fertility treatment — Follistatin binds activin, which is crucial for FSH regulation and follicular development. Do not use during IVF cycles, assisted reproduction, or when actively trying to conceive.
- Known reproductive hormone disorders — conditions involving FSH, LH, or gonadotropin dysregulation may be worsened by exogenous Follistatin.
- Autoimmune conditions — TGF-β family members play roles in immune regulation. Modulating this axis in the presence of autoimmune disease carries unknown risks.
- Age under 25 — growth plate closure, hormonal axis development, and reproductive maturation make Follistatin inappropriate for younger individuals.
Monitoring Recommendations
- FSH and LH levels: Check before the first cycle and 4–6 weeks after cycle completion to assess reproductive axis impact
- Testosterone (men): Monitor alongside FSH/LH to detect any downstream effects on testicular function
- Menstrual regularity (women): Track cycle length and regularity before, during, and after Follistatin use
- IGF-1 levels: Optional but useful to see if Follistatin (especially when stacked with GH secretagogues) is affecting the GH/IGF-1 axis
- General health markers: CBC, CMP, and liver function as a baseline and after the first cycle
Common Follistatin Dosing Mistakes
Avoid these common errors to get the most out of your Follistatin protocol:
Frequently Asked Questions
Key Takeaways
- Follistatin 344 is a myostatin inhibitor — it binds and neutralizes myostatin, theoretically removing the brake on skeletal muscle growth
- Standard dose: 100–200 mcg SubQ daily for 10–30 day cycles, 1–3 times per year with extended off-periods
- The biology is real; the peptide injection evidence is limited — myostatin science and gene therapy results are strong, but human data for subcutaneous Follistatin peptide injection is minimal
- FS-344 is the standard variant — it is processed in vivo to FS-315 (circulating, myostatin-binding) and FS-288 (tissue-bound, gonad-concentrated)
- Cycling is essential: 10–30 days on, with off-periods 2–3 times the cycle length. Not used continuously.
- Reproductive considerations are real: Follistatin binds activin, which regulates FSH. Monitor reproductive hormones, especially if fertility is a concern
- Best stacks: IGF-1 LR3 for growth factor synergy, MK-677 for GH elevation, or BPC-157 for recovery support
- Handle with care: Follistatin is a large protein — reconstitute gently (no shaking), refrigerate after reconstitution, use within 14–21 days
- Training and nutrition are non-negotiable — myostatin inhibition removes a constraint but does not replace the growth stimulus from progressive overload training and adequate protein
- Set realistic expectations: Do not expect gene therapy or myostatin knockout animal results from peptide injection. Effects, if any, will be subtle and develop over multiple cycles.
- Not FDA-approved — classified as a research peptide. No pharmaceutical-grade standard exists for human injection. Check local regulations.
This article is for educational and informational purposes only. See our Disclaimer.
References
- Lee SJ, McPherron AC. “Regulation of myostatin activity and muscle growth.” Proc Natl Acad Sci USA. 2001;98(16):9306-9311. PubMed
- McPherron AC, Lawler AM, Lee SJ. “Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member.” Nature. 1997;387(6628):83-90. PubMed
- Mendell JR, et al. “A phase 1/2a follistatin gene therapy trial for Becker muscular dystrophy.” Mol Ther. 2015;23(1):192-201. PubMed
- Mendell JR, et al. “Follistatin gene therapy for sporadic inclusion body myositis improves functional outcomes.” Mol Ther. 2017;25(4):870-879. PubMed
- Amthor H, et al. “Follistatin complexes myostatin and antagonises myostatin-mediated inhibition of myogenesis.” Dev Biol. 2004;270(1):19-30. PubMed
- Rodino-Klapac LR, et al. “Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease.” Muscle Nerve. 2009;39(3):283-296. PubMed
- Nakatani M, et al. “Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology.” FASEB J. 2008;22(2):477-487. PubMed
- Phillips DJ, de Kretser DM. “Follistatin: a multifunctional regulatory protein.” Front Neuroendocrinol. 1998;19(4):287-322. PubMed
- Sidis Y, et al. “Biological activity of follistatin isoforms and follistatin-like-3 is dependent on differential cell surface binding and specificity for activin, myostatin, and bone morphogenetic proteins.” Endocrinology. 2006;147(7):3586-3597. PubMed
- Lee SJ. “Quadrupling muscle mass in mice by targeting TGF-beta signaling pathways.” PLoS One. 2007;2(8):e789. PubMed
Next Steps
Continue your research with these resources.
IGF-1 LR3 Dosage Guide
Learn dosing protocols for IGF-1 LR3 — the most synergistic growth factor to stack with Follistatin for muscle growth.
Read GuideDosage Calculator
Calculate your exact Follistatin 344 dose based on vial size and reconstitution volume.
Open CalculatorPeptide Directory
Browse all peptides with research summaries and dosing data.
View Directory